- Ipsen SA IPSEY and IRLAB have signed a licensing agreement, providing Ipsen exclusive rights to mesdopetam.
- Under the terms of the agreement, IRLAB will be eligible to receive up to $363 million, including an upfront cash payment of $28 million and up to $335 million in milestone payments.
- IRLAB is also eligible to receive tiered low double-digit royalties on worldwide net sales of mesdopetam.
- Mesdopetam (IRL790) is a dopamine D3-receptor antagonist being developed to prevent and treat levodopa-induced dyskinesias and psychosis in Parkinson’s.
- Price Action: IPSEY shares traded at 25.71 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
